WallStSmart
CELU

Celularity Inc

NASDAQ: CELU · HEALTHCARE · BIOTECHNOLOGY

$0.81
-3.77% today

Updated 2026-06-03

Market cap
$28.80M
P/E ratio
P/S ratio
1.09x
EPS (TTM)
$-3.59
Dividend yield
52W range
$1 – $4
Volume
0.1M

Celularity Inc (CELU) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item20182019202020212022202320242025
Operating cash flow$-543.00$-1.10M$-63.19M$-110.10M$-137.88M$-38.69M$-6.40M$-13.25M
Capital expenditures$1.92M$3.00$27.83M$6.20M$5.24M$4.05M$161000.00$0.00
Depreciation
Stock-based comp$4.50M$3.67M$4.37M$40.01M$15.86M$15.02M$11.57M$10.38M
Free cash flow$-1.92M$-1.10M$-91.03M$-116.30M$-143.11M$-42.73M$-6.56M$-13.25M
Investing cash flow
Financing cash flow
Dividends paid$39.07M$0.00$5.90M
Share repurchases
Debt repayment
Net change in cash$892300.00$-602311.00

Frequently asked questions

What is Celularity Inc's revenue?

Celularity Inc's trailing twelve-month revenue is $26.55M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is CELU?

In its most recent fiscal year, CELU ran a gross margin of 76.04%, an operating margin of -230.92%, and a net margin of -345.76%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does CELU generate?

CELU produced $-13.25M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is CELU's balance sheet healthy?

CELU holds $6.17M in cash and equivalents against — in long-term debt, on $-38.06M of shareholder equity. That debt is best read against the cash flow the business throws off each year.